The current study reveals that the functional role of antioxidant enzymes is cellular context and treatment agents dependent; targeting catalase may represent a novel strategy to improve the efficacy of As2O3 in CML treatment. Here, CAT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.